Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2025
Date Filed: April 17, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of an exhibit submission rather than a financial results announcement.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document focuses on the submission of an Options Prospectus.
Guidance, Outlook, and Unusual Items
Exhibit Submitted: Exhibit 99.1 - Options Prospectus.
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Management Commentary: The filing contains no specific management commentary, guidance, or risk factors beyond the standard incorporation of the Options Prospectus.
Investor Verification Checklist
- Review the attached Options Prospectus (Exhibit 99.1) for details on the terms, dilution impact, and exercise conditions of the new options.
- Verify the status of the referenced Form S-8 and Form F-3 registration statements to understand the capital raising context.
- Confirm the company's current cash position and runway, as this filing does not disclose updated financial metrics.